Lihui Han, M.D., Ph.D.，Professor
Gender:Female Date of Birth:Oct 12, 1974 Marriage Status:Married
Office Address:Room 6522, Building 6, Dept. of Immunology,
Shandong University School of Basic Medical Science,
44 Wenhua Xi Road, Jinan, shandong, P.R.China 250012
Phone:86-531-8382038 FAX:86-531-88382084 Mobile: 86-13021737958
E-mail:hanlihui@sdu.edu.cn;hanlihui@yahoo.com
Education
1993.9 - 1998.7 MD Shandong Medical University (Medicine)
1998.9 - 2003.7 Ph.D Medical school,shandong university(Immunology)
2009.9 - 2010.9 Post-Doc Beth Israel Deaconess Medical Center,
Harvard University, USA(Immunology)
Scientific Training
2002.4-2003.4Visiting Scholar Dept. of Microbiology and Immunology
Medical Center, University of Kentucky, USA
Faculty Appointments
2003 - 2006 Instructor, Department of Immunology, Medical School,
Shandong University, China
2006 - 2011 Associate Professor, Department of Immunology,
Medical School, Shandong University, China
2011 – now Professor, Department of Immunology, Medical School,
Shandong University, China
Memberships in Professional and Scientific Societies
2003-now Member, Chinese Society of Immunology
2004-now Member, Chinese Society of Microbiology
Research Interest
1.The molecular mechanism involved in the metastatic process of hepatocarcinoma and its intervention. We mainly focus on the screening and identification of new markers for hepatocarcinoma metastasis and its molecular intervention.
2.The signaling transduction process of immune signals. We mainly focus on the intercellular and intracellular immune signaling transduction process in the conditions of inflammation and tissue damage.
3.The pathogenesis of autoimmune disease. We mainly focused on the molecular mechanism involved in the pathogenesis of autoimmune diseases.
Major Teaching Responsibilities at Shandong University
Medical Immunology，for medical students
Infection and Immunity, for medical students
Medical Immunology Experimental Class, for medical students
Genetic Engineering, for medical students
Medical Immunology, for postgraduate students
Advances in Cellular and Molecular Immunology, for postgraduate students
Technology of Immunology, for postgraduate students
Technology of Genetic Engineering, for postgraduate students
Publications
1.Huai W, Zhao R, Song H, Zhao J, Zhang L, Zhang L, Gao C,Han L*, Zhao W*.Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription .Nat Commun. 2014 Aug 20;5:4738.(IF=11.9) *Corresponding author
2.Sun X#,Han LH#, Seth P, Bian S, Li L, Csizmadia E, Junger WG, Schmelzle M, Usheva A, Tapper EB, Baffy G, Sukhatme VP, Wu Y, Robson SC.Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.Hepatology.2013 Jan;57(1):205-16.(IF=12) #Co-first author
3.Guo P, Ma X, Zhao W, Huai W, Li T, Qiu Y, Zhang Y,Han L*.TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.Oncogene.2018 Jan 25;37(4):478-488.(IF=7.9)*Corresponding author
4.Ma X, Ma X, Qiu Y, Zhu L, Lin Y, You Y, Ma D, Qin Z, Sun C, Zhao Y, Sun Y,Han L*.TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation.Cell Death Dis. 2018 May 22;9(6):608.(IF=6.17)*Corresponding author
5.Ma XM, Guo PB, Qiu YM, Mu K, Zhu LH, Zhao W, Li T,Han LH*.Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.Oncotarget.2016 Jun 14;7(24):36185-36197.doi: 10.18632/oncotarget. 9154.(IF=5.4)*Corresponding author
6.Zhang Y, Li T, Guo PB, Kang J, Wei Q, Jia XQ, Zhao W, Huai WW, Qiu YM, Sun L,Han LH*.MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression.Sci Rep.2014, Sep 1;4:6248.(IF=5.597) *Corresponding author
7.Qiu Y, Liu P, Ma X, Ma X, Zhu L, Lin Y, You Y, Yu W, Ma D, Sun C, Qin Z, Zhao Y, Shi J,Han L*.TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.Biochim Biophys Acta Mol Cell Res.2019 Sep;1866(9): 1412-1420.(IF=5.2) *Corresponding author
8.Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia XQ, Zhao W, Huai WW, Guo PP,Han LH*.Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression.Lab Invest.2014 Jan;94(1):52-62. (IF=4.385) *Corresponding author
9.Wei Q, Guo PB, Mu K, Zhang Y, Zhao W, Huai WW, Qiu YM, Li T, Ma XM, Liu YF, Chen XY,Han LH*.Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome.Lab Invest.2015 Jul;95(7):804-16. (IF=4.385) *Corresponding author
10.Yang QR，Yu CC, Yang ZW, Wei Q, Mu K, Zhang Y, Zhao W, Wang XF，Huai WW,Han LH*.Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus.J RHEUMATOL. 2014 Mar;41(3): 444-52.(IF=3.544) *Corresponding author
11.Guo P, Qiu Y, Ma X, Li T, Ma X, Zhu L, Lin Y,Han L*.Tripartite motif 31 promotes resistance to anoikis of hepatocarcinoma cells through regulation of p53-AMPK axis.Exp Cell Res.2018 Jul 1;368(1):59-66.(IF=3.5)*Corresponding author
12.Wei Q, Zhang Y, Sun L, Jia XQ, Huai W, Yu CC, Wan ZK,Han LH *.High dose of extracellular ATP switched autophagy to apoptosis in anchorage-dependent and anchorage-independent hepatoma cells.Purinergic Signal.2013 Dec;9(4):585-98.(IF=3.5) *Corresponding author
13.Sun L, Li T, Wei Q, Zhang Y, Jia X, Wan Z,Han L*.Upregulation of BNIP3 mediated by ERK/HIF-1α pathway induces autophagy and contributes to anoikis resistance of hepatocellular carcinoma cells.Future Oncol.2014 Jun;10(8):1387-98.(IF=3.2) *Corresponding author
14.Yang Z, Cao J, Yu C, Yang Q, Zhang Y, Han L*. Caspase-1 mediated interleukin-18 activation in neutrophils promotes the activity of rheumatoid arthritis in a NLRP3 inflammasome independent manner. Joint Bone Spine. 2016 May;83(3):282-9.(IF=2.9)*Corresponding author
15.Zhang Y, Li T, Qiu Y, Zhang T, Guo P, Ma X, Wei Q,Han L*.Serum microRNA panel for early diagnosis of the onset of hepatocellular carcinoma.Medicine (Baltimore).2017 Jan;96(2):e5642. (IF=2.1)*Corresponding author
16.Yang ZW, Cao J, Yang QR, Zhang YC,Han LH *.NLRP3 p.Q705K and CARD8 p.C10X single nucleotide polymorphism are not associated with susceptibility to rheumatoid arthritis: a meta-analysis.International Journal of Rheumatic Diseases.2017 Oct;20(10):1481-1491.(IF=2.0)*Corresponding author
17.Han LH*,Zhao YS,Jia XQ. Mathematical modeling identified c-FLIP as an apoptotic switch in death receptor induced apoptosis.Apoptosis.2008 Oct;13(10):1198-204.(IF=4. 6) *Corresponding author
Editorial Comment：Richard A. Lockshin. An attempt to understand the multiparametric control of the initiation of apoptosis.Apoptosis.2008 Oct;13(10):1195-7.
18.Zhang ZY, Cao LL, Li J, Liang XL, Liu YG, Liu H, Du J, Qu ZH, Cui M, Liu SX, Gao LF, Ma CH, Zhang LN,Han LH*,Sun WS*. Acquisition of anoikis resistance reveals a synoikis-like survival style in BEL7402 hepatoma cells.Cancer Lett.2008 Aug 18;267(1):106-15.(IF=4.544)*Corresponding author
19.Cao LL, Han LH*, Zhang ZY, Li J, Qu ZH, Du J, Liang XH, Liu YG, Liu H, Shi YY, Liu SX, Gao LF, Sun WS*.Involvement of anoikis-resistance in the metastasis of hepatoma cells.EXP CELL RES.2009 Apr 15;315(7):1148-56.(IF=3.95)*Corresponding author
20.Zhang ZY#,Han LH#,Liu YG,Liang XH,Sun WS.Up-regulation of Tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations.Mol Biol Rep.2009 May;36(5):1211-6. (IF=2.9) #Co-first author
21.Zhang ZY#,Han LH#, Liang XH, Cao LL, Sun WS.A PCR based method to construct small interference RNA expression vectors.Mol Biol Rep. 2009 Apr;36(4):801-5.(IF=2.9)#Co-first author
22.Han LH, Zhang ZY, Qin W, Sun WS.Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients?Med Hypotheses. 2007;68(2):407-9. (IF=1.4)
23.Zhang ZY#,Han LH#, Cao LL, Liang XH, Liu YG, Liu H, Du J, Qu ZH, Zhu CJ, Liu SX, Li H, Sun WS.Aggregation formation mediated anoikis resistance of BEL7402 hepatoma cells. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA.2008;46(3): 331-336. (IF=1.2)#Co-first author
Patents
1.Han LH, Zhang Y, Li T, Qiu YM, Jia XQ, Zhao W, Huai WW, Guo PB, Kang J，Jiang YY. Application of sera microRNA as early metastatic marker for hepatocellular carcinoma. Chinese Patent No. 2014101879887
2.Han LH, Li T, Zhang Y, Jia XQ, Zhao W, Qiu YQ, Kang J, Jiang YY, Huai WW, Guo PB. Application of sera microRNA as diagnostic marker for hepatocellular carcinoma. Chinese Patent No. ZL201410184082X
3.Han LH, Zhang Y, Li T, Zhao W, Wei Q，Huai WW, Guo PB. Application of miR-424-5p in inhibiting the metastasis of hepatocarcinoma. Chinese Patent No. ZL2014101870416
4.Han LH,Sun WS, Zhang ZY, Cao LL, Liang XH, Qu ZH, Du J, Ma T, Hou N,Guo C.A model to simulate the metastasis of glioma cells.Chinese Patent No.ZL200710113294.9
5.Sun WS, Zhang ZY,Han LH,Cao LL, Ju Y, Du J, Ma T, Hou N,Qu ZH, Liu YG. A PCR based method to construct small interference RNA expression vectors，Chinese Patent No.ZL200710015333.14．
6.Sun WS,Han LH, Cao LL, Liang XH, Du J, et al. A novel method for successful transfection of tumor cells. Chinese Patent Application No. ZL200910255648.2．
Grant Support
1．The effect and molecular mechanism of cGAS in the progression of hepatocellular carcinoma,National Nature Science Foundation of China ( No. 81972275)
2020.1-2024.12
Principle Investigator
2．The anti-tumor effect of NOD2 on hepatocarcinoma progression through MAPK pathway,National Nature Science Foundation of China ( No. 81672391)
2017.1-2020.12
Principle Investigator
3．The role of TRIM31 in the progression of HCC through regulation of NLRP3 inflammasome
National Nature Science Foundation of China ( No. 81472269)
2015.1-2018.12
Principle Investigator
4．Involvement of mir-424 in anoikis-resistance of hepatoma cells.
National Nature Science Foundation of China ( No.81172352)
2012.1-2015.12
Principle Investigator
5．Identification of key driver molecule for hepatocellular carcinoma and its targeted reversion
Major Innovation Project of Shandong Province (No. 2018CXGC1217)
2018.1-2020.12
Principle Investigator
6．Use of microRNA expression profile to predict the metastasis potential of hepatoma
Technology development Project of Shandong Province, China (2011GSF11825)
2011.1-2013.12
Principle Investigator
7．Screening and identification of the key molecules responsible for resistance of hepatocarcinoma cells to anoikis
National Nature Science Foundation of China( No.30700357)
2008.1-2010.12
Principle Investigator
Scientific honors
1.Han LH, Sun WS, Zhang ZY, Cao LL, Ma CH et al.
Mechanism involved in anoikis-resistance of hepatocarcinoma cells and its related gene therapy strategy.
Second Prize of Scientific Technology in Shandong Province, China. (2011)
2.Han LH, Sun WS, Zhang ZY, Cao LL, Ma CH et al.
Gene therapy strategy by targeting anoikis-resistant hepatocarcinoma cells and its application.
First Prize of Scientific Technology in Jinan City, China . (2009)
3.Han LH, Li T, Zhang Y, Zhao W, Ma XM, et al
The effect of microRNA on the metastatic hepatocarcinoma and its clinicalapplication。
First Prize of Scientific Research from the high education in Shandong Province, China. (2016)
4.Han LH, Li T, Zhang Y, Zhao W, Guo PB, et al.
The role of microRNA in the progression of hepatocarcinoma and its clinical application
Second Prize of Medical Research in Shandong Province, China. (2015)
5.Liu SX,Han LH, Sun WS, Guo C et al.
Selective block the key molecule to prevent HBV infection induced hepatocarcinoma.
Third Prize of Scientific Technology in Shandong Province, China. (2006)
